Market revenue in 2023 | USD 614.2 million |
Market revenue in 2030 | USD 551.0 million |
Growth rate | -1.5% (CAGR from 2023 to 2030) |
Largest segment | Opioids |
Fastest growing segment | NSAIDs and Others |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Opioids was the largest segment with a revenue share of 26.49% in 2023. Horizon Databook has segmented the Canada cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
Canada cancer supportive care drugs market is expected to decline over the forecast period. Like the U.S., Canada is also facing opioid epidemic, which restricts opioid prescription to some extent for cancer pain treatment. In addition, there is high usage of precision medicine such as ADC for cancer treatments in countries such as Canada, which has very few side effects related to CINV. These factors may hamper market growth over the forecast period.
Factors such as high cancer prevalence and approval of new products in the region is expected to drive market growth. As per World Cancer Research Fund, In 2021, an estimated 229,200 new cancer cases were diagnosed in Canada. Breast, lung, prostate, colorectal cancers accounted for about 46% of all diagnoses. Moreover, the prevalence of cancer is expected to increase over the forecast period as a result of growing geriatric population in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Canada cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account